A nationwide survey of SARS-CoV-2 antinucleocapsid seroprevalence among blood donors in Japan revealed that, as of November 2022, infection-induced seroprevalence of the population was 28.6% (95% CI 27.6%-29.6%). Seroprevalence studies might complement routine surveillance and ongoing monitoring efforts to provide a more complete real-time picture of COVID-19 burden.
Keywords: COVID-19; Japan; SARS-CoV-2; respiratory infections; seroepidemiology; seroprevalence; surveillance; viruses; zoonoses.